Back to Search
Start Over
Bullous disorders associated with PD-1 and PD-L1 inhibitors: Pharmacovigilance analysis of the United States Food and Drug Administration Adverse Event Reporting System from the Research on Adverse Drug Events And Reports Program.
- Source :
-
Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2020 Sep; Vol. 83 (3), pp. 955-957. Date of Electronic Publication: 2020 Jan 31. - Publication Year :
- 2020
- Subjects :
- B7-H1 Antigen immunology
Humans
Programmed Cell Death 1 Receptor immunology
Skin Diseases, Vesiculobullous chemically induced
Skin Diseases, Vesiculobullous immunology
United States epidemiology
United States Food and Drug Administration statistics & numerical data
Adverse Drug Reaction Reporting Systems statistics & numerical data
B7-H1 Antigen antagonists & inhibitors
Immune Checkpoint Inhibitors adverse effects
Pharmacovigilance
Programmed Cell Death 1 Receptor antagonists & inhibitors
Skin Diseases, Vesiculobullous epidemiology
Subjects
Details
- Language :
- English
- ISSN :
- 1097-6787
- Volume :
- 83
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Journal of the American Academy of Dermatology
- Publication Type :
- Editorial & Opinion
- Accession number :
- 32014533
- Full Text :
- https://doi.org/10.1016/j.jaad.2020.01.059